Zacks: Brokerages Anticipate Evoke Pharma Inc (EVOK) Will Announce Earnings of -$0.10 Per Share

Wall Street brokerages forecast that Evoke Pharma Inc (NASDAQ:EVOK) will report earnings of ($0.10) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Evoke Pharma’s earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.17). Evoke Pharma reported earnings of ($0.24) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 58.3%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, November 13th.

According to Zacks, analysts expect that Evoke Pharma will report full-year earnings of ($0.49) per share for the current financial year, with EPS estimates ranging from ($0.63) to ($0.40). For the next year, analysts anticipate that the company will report earnings of ($0.58) per share, with EPS estimates ranging from ($0.83) to ($0.33). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings results on Thursday, August 9th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.02.

EVOK has been the topic of a number of recent research reports. ValuEngine upgraded shares of Evoke Pharma from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. HC Wainwright set a $9.00 price objective on Evoke Pharma and gave the stock a “buy” rating in a research report on Thursday, May 3rd. Finally, Zacks Investment Research upgraded Evoke Pharma from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research report on Tuesday, May 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $7.83.

Shares of Evoke Pharma traded down $0.12, reaching $2.52, during mid-day trading on Friday, according to Marketbeat.com. The stock had a trading volume of 25,701 shares, compared to its average volume of 36,337. The firm has a market cap of $44.29 million, a P/E ratio of -3.04 and a beta of 1.46. Evoke Pharma has a 12 month low of $1.85 and a 12 month high of $4.09.

An institutional investor recently bought a new position in Evoke Pharma stock. Deutsche Bank AG acquired a new position in Evoke Pharma Inc (NASDAQ:EVOK) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 200,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $452,000. Deutsche Bank AG owned 1.30% of Evoke Pharma at the end of the most recent quarter. Institutional investors and hedge funds own 13.78% of the company’s stock.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

See Also: How do investors use RSI to grade stocks?

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply